Derek Lowe is terrific in communicating complex ideas in the field to concerned lay observers like me; he's been a great resource for reliable information about the science of this thing.

Just to clarify; the ChAdOx1 MERS prospect hasn't proceeded to a trial demonstrating efficacy in human subjects (as yet).

That's a particularly important distinction here, given the nature of the novel delivery mechanism[1] and prior observation of complications in SARS-CoV-1 vaccine development[2]

[1] https://en.wikipedia.org/wiki/Viral_vector#Adenoviruses

[2] https://www.hkmj.org/abstracts/v22n3%20Suppl%204/25.htm